Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.

Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M.

Breast Cancer Res Treat. 2010 Aug;123(1):51-8. doi: 10.1007/s10549-009-0631-7. Epub 2009 Nov 10.

2.

Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.

Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E.

Clin Cancer Res. 2006 Nov 1;12(21):6359-66.

3.
4.

Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.

Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA.

Oncologist. 2011;16(12):1675-83. doi: 10.1634/theoncologist.2011-0196. Epub 2011 Dec 6.

5.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
6.

Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.

Liao GS, Dai MS, Hsu HM, Chu CH, Hong ZJ, Fu CY, Chou YC, Huang TC, Yu JC.

Eur J Surg Oncol. 2017 Oct;43(10):1855-1861. doi: 10.1016/j.ejso.2017.07.001. Epub 2017 Jul 19.

PMID:
28756019
7.
9.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
10.

Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.

Cubukcu E, Kanat O, Fatih Olmez O, Kabul S, Canhoroz M, Avci N, Deligonul A, Hartavi M, Cubukcu S, Olmez F, Kurt E, Evrensel T, Gokgoz S, Manavoglu O.

J BUON. 2013 Apr-Jun;18(2):359-65.

PMID:
23818346
11.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

12.

HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women.

Li MH, Hou CL, Wang C, Sun AJ.

Pathol Res Pract. 2016 Apr;212(4):252-7. doi: 10.1016/j.prp.2015.11.019. Epub 2016 Feb 1.

PMID:
26899763
13.

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P.

J Pathol. 2004 Mar;202(3):265-73.

PMID:
14991891
14.

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X.

Oncologist. 2013 Jun;18(6):667-74. doi: 10.1634/theoncologist.2012-0350. Epub 2013 May 30.

15.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.

PMID:
24715381
16.

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.

Rydén L, Jirström K, Haglund M, Stål O, Fernö M.

Breast Cancer Res Treat. 2010 Apr;120(2):491-8. doi: 10.1007/s10549-010-0758-6. Epub 2010 Feb 5.

PMID:
20135347
17.

The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

Kuo WH, Chang LY, Liu DL, Hwa HL, Lin JJ, Lee PH, Chen CN, Lien HC, Yuan RH, Shun CT, Chang KJ, Hsieh FJ.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):135-45. Erratum in: Taiwan J Obstet Gynecol. 2007 Sep;46(3):320-1.

18.

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.

Zhao P, Lu Y, Jiang X, Li X.

Cancer Sci. 2011 May;102(5):1107-11. doi: 10.1111/j.1349-7006.2011.01894.x. Epub 2011 Feb 28.

19.

The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.

Zhu YY, Si W, Ji TF, Guo XQ, Hu Y, Yang JL.

Tumour Biol. 2016 Jun;37(6):7675-84. doi: 10.1007/s13277-015-4649-7. Epub 2015 Dec 21.

PMID:
26687919
20.

Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.

Yue Y, Astvatsaturyan K, Cui X, Zhang X, Fraass B, Bose S.

PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.

Supplemental Content

Support Center